

# 学位論文 博士（医学） 甲

*SLC22A3* that encodes organic cation transporter-3  
is associated with prognosis and immunogenicity  
of human lung squamous cell carcinoma

(有機カチオントランスポーター-3 をコードする *SLC22A3* は  
ヒト肺扁平上皮癌の予後および免疫原性に関連する)

NGUYEN THUY AN

山梨大学



# ***SLC22A3* that encodes organic cation transporter-3 is associated with prognosis and immunogenicity of human lung squamous cell carcinoma**

Thuy-An Nguyen<sup>1</sup>, Minh-Khang Le<sup>2</sup>, Phuc-Tan Nguyen<sup>1</sup>, Nguyen Quoc Vuong Tran<sup>1^</sup>, Tetsuo Kondo<sup>2</sup>, Atsuhito Nakao<sup>1,3,4^</sup>

<sup>1</sup>Department of Immunology, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan; <sup>2</sup>Department of Human Pathology, University of Yamanashi, Yamanashi, Japan; <sup>3</sup>Yamanashi GLIA Center, University of Yamanashi, Yamanashi, Japan; <sup>4</sup>Atopy Research Center, Juntendo University School of Medicine, Tokyo, Japan

**Contributions:** (I) Conception and design: TA Nguyen, MK Le, NQV Tran; (II) Administrative support: T Kondo, A Nakao; (III) Provision of study materials or patients: TA Nguyen, MK Le; (IV) Collection and assembly of data: TA Nguyen, MK Le; (V) Data analysis and interpretation: TA Nguyen, MK Le, NQV Tran; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

**Correspondence to:** Atsuhito Nakao, MD, PhD. Yamanashi GLIA Center, University of Yamanashi, Yamanashi, Japan; Atopy Research Center, Juntendo University School of Medicine, Tokyo, Japan; Department of Immunology, Faculty of Medicine, University of Yamanashi, 1110 Shimokato, Chuo, Yamanashi 409-3821, Japan. Email: anakao@yamanashi.ac.jp; Nguyen Quoc Vuong Tran, MD, PhD. Department of Immunology, Faculty of Medicine, University of Yamanashi, 1110 Shimokato, Chuo, Yamanashi 409-3821, Japan. Email: vtran@yamanashi.ac.jp.

**Background:** *SLC22A3*, the gene which encodes organic cation transporter (OCT)-3, has been linked to the prognosis of several types of cancer. However, its role in lung squamous cell carcinoma (LSCC) has not been addressed elsewhere.

**Methods:** We analyzed gene expression, DNA methylation, and clinicopathological data from The Cancer Genome Atlas - Lung Squamous Cell Carcinoma (TCGA-LUSC) (n=501), a publicly available database exclusively consisting of LSCC patients. Using a 5 FPKM (fragments per kilobase of exon per million mapped fragments) cut-off, we divided LSCC patients into two groups: patients with tumors possessing high and low *SLC22A3* expression (*SLC22A3*-high and *SLC22A3*-low, respectively). Prognostic significance was determined through Cox analyses and Kaplan-Meier curves for overall survival (OS) and disease-free survival (DFS). Differential methylation position (DMP), differentially gene expression, and pathway analyses were performed. Validation was carried out in GSE74777 (n=107), GSE37745 (n=66), GSE162520 (n=45) and GSE161537 (n=17).

**Results:** *SLC22A3*-high LSCC patients had lower OS and DFS rates than *SLC22A3*-low LSCC patients. The different expression levels of *SLC22A3* in LSCC were correlated with the methylation status of the *SLC22A3* gene. Pathway analysis indicated that *SLC22A3* expression levels were positively correlated with immune-related pathways such as inflammatory response and abundance of infiltrating immune cells in the tumor microenvironment (TME). Notably, in the *SLC22A3*-high group, many genes encoding immunological checkpoint inhibitory molecules were upregulated. In addition, *SLC22A3* expression positively correlated with the Hot Oral Tumor (HOT) score, indicating high tumor immunogenicity.

**Conclusions:** These findings suggest that high expression of *SLC22A3* is associated with poor prognosis and high immunogenicity in LSCC tumors.

**Keywords:** Lung squamous cell carcinoma (LSCC); *SLC22A3*; biomarker; tumor microenvironment (TME); inflammation

<sup>^</sup> ORCID: Nguyen Quoc Vuong Tran, 0000-0003-4038-2704; Atsuhito Nakao, 0000-0002-4222-8922.

Submitted May 24, 2023. Accepted for publication Sep 26, 2023. Published online Oct 27, 2023.

doi: 10.21037/tlcr-23-334

View this article at: <https://dx.doi.org/10.21037/tlcr-23-334>

## Introduction

For decades, lung cancer has consistently ranked the deadliest cancer globally (1). Lung cancer has two main types: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), which account for 85% and 15% of all cases, respectively ([www.cancer.org](http://www.cancer.org), accessed on July 24, 2023). Based on the histological characteristics, NSCLC is further classified as lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LSCC), large cell (undifferentiated) carcinoma, and others. LSCC accounts for nearly 20% of all lung cancer (2).

The 5-year relative survival rate of patients with LSCC increased over time but remained poor, reaching only 24.2% in 2020 (3). Although the introduction of targeted therapy in recent years has shown remarkable improvements in survival outcomes for LUAD patients, LSCC patients have seen modest benefits from these advanced therapies, even detrimental (4). This is partly due to the differences in the biology and genetics of the two types of lung cancer. LSCC has a limited number of genetic alterations that can be targeted, such as *EGFR*, *KRAS* mutations, and *ALK* rearrangements, making it challenging to develop effective therapeutic strategies. In addition, although LSCC treatment has revolutionized thanks to immune checkpoint

blockade therapy, a sizable portion of LSCC patients is resistant to immune checkpoint inhibitors (5,6). To tackle these challenges in developing therapeutic remedies for LSCC patients, it is essential to gain a deeper understanding of molecular abnormalities underlying LSCC tumors.

*SLC22A3* gene encodes organic cation transporter (OCT)-3—a member of the OCT family which transports a range of exogenous and endogenous organic cations, including norepinephrine, dopamine, histamine, and certain drugs, across plasma membranes. OCT-3 is found in many types of tissues throughout the body, including the lung, liver, kidney, small intestine, and others (7,8). Several studies have linked OCT-3 to the prognosis of various cancer types with varying impacts. While on the one hand, overexpression of *SLC22A3* was associated with prolonged survival in patients with pancreatic cancer (9) and glioblastoma multiforme (10); on the other hand, colorectal and cervical cancer patients experienced unfavorable outcomes when *SLC22A3* was highly expressed (11,12). Furthermore, alteration in *SLC22A3* expression has been shown to influence the sensitivity of tumor cells to chemotherapeutic medication in kidney carcinoma, colorectal cancer, and head and neck squamous cell cancer (13-15). These studies implied that *SLC22A3* may influence cancer prognosis and treatment responsiveness.

To the best of our knowledge, the impact of *SLC22A3* expression on LSCC has not been addressed elsewhere. Therefore, the current work sought to evaluate gene expression, DNA methylation, and clinicopathological characteristics data of the first sample of primary LSCC retrieved from The Cancer Genome Atlas - Lung Squamous Cell Carcinoma (TCGA-LUSC) project, exclusively consisting of LSCC patients. We present this article in accordance with the REMARK reporting checklist (available at <https://tlcr.amegroups.com/article/view/10.21037/tlcr-23-334/rc>).

## Methods

### Data processing

TCGA-LUSC (n=504) is one of the largest projects in the TCGA program (The Cancer Genome Atlas, National

### Highlight box

#### Key findings


- *SLC22A3* gene expression was associated with worse prognoses in lung squamous cell carcinoma (LSCC) patients and intense levels of inflammation in the LSCC tumor microenvironment (TME).

#### What is known and what is new?

- *SLC22A3* has been linked to the prognoses of several types of cancer.
- This study found that high *SLC22A3* expression is associated with poor prognosis and positively correlated with immune-related pathways such as inflammatory response and abundance of infiltrating immune cells in the TME.

#### What is the implication, and what should change now?

- *SLC22A3* may become as a biomarker for prognosis in LSCC.
- *SLC22A3* may play a role in the development of inflammatory microenvironment in LSCC.



**Figure 1** Flow of LSCC patients from TCGA-LUSC project through the study. LSCC, lung squamous cell carcinoma; TCGA-LUSC, The Cancer Genome Atlas - Lung Squamous Cell Carcinoma;  $N_p$ , number of patients;  $N_s$ , number of samples; DEGA, differentially expressed gene analysis; GSA, gene set variation analysis, HOT score, Hot Oral Tumor score.

Cancer Institute, USA), exclusively consists of LSCC patients. We accessed the TCGA-LUSC and retrieved data about gene expression, DNA methylation, and clinicopathological characteristics. First, we established the criteria for a sample to represent a case in our study as the first sample of the primary tumor. Normal tissue, later samples of the primary tumor, or recurrent tumors were not included (Figure 1). Patients were involved in this study

regardless of treatment strategy. Then, we extracted raw data from gene expression and DNA methylation.

Regarding gene expression data, we applied the following layers of filter: (I) data category of transcriptome profiling; (II) data type of gene expression quantification; and (III) workflow type of STAR—counts. A total of 60,660 read counts within 553 samples comprise the expression matrix. After applying the sample criteria, 501 samples of primary

tumors, each of which corresponds to an LSCC case, were included in our analyses.

Regarding DNA methylation data, we used (I) data type of methylation beta value; (II) workflow type of SeSAMe methylation beta estimation; and (III) illumina human methylation 450. A report of methylation status in 450,000 CpG sites within 412 samples was collected. Using the mentioned sample criteria, 369 samples with available DNA methylation information remained.

Finally, we retrieved the clinicopathological parameters, such as age, gender, race, TNM stages, the American Joint Committee on Cancer (AJCC) stages, chemotherapy, radiation therapy, overall survival (OS) time, OS status, disease-free survival (DFS) time, and DFS status. OS time is calculated as the time interval in months from LSCC diagnosis to death, regardless of LSCC or other causes. DFS is the time-period in months between LSCC diagnosis and clinical relapse. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013).

### *DNA methylation analysis*

We employed the ChAMP package (16) to perform differential methylation position (DMP) analysis. The primary purpose of this analysis section was to examine the methylation status of CpG sites within the *SLC22A3* gene, including the gene promoter and body. Therefore, other methylation regions were not accounted for in the present study.

### *Differentially expressed gene analysis (DEGA) and pathway analysis*

In the DEGA pipeline, we initially employed three panels, including nCounter Human PanCancer Pathways (CHPP), nCounter Human PanCancer Immune Profile (CHIP), and nCounter Human PanCancer Progression (CHPPr). Such panels consist of 770, 772, and 770 genes of interest, among which there are 40, 40, and 30 internal reference genes, respectively. These reference genes were discarded before further analyses. Cancer-related genes involved in 13 classic cancer pathways comprise the CHPP panel, while CHIP includes genes from different immune cell types, common checkpoint inhibitors, CT antigens, and adaptive and innate immune responses. Conversely, the CHPPr panel consists of genes related to angiogenesis, extracellular matrix remodeling, and epithelial-to-mesenchymal transition (EMT). CHPP, CHIP, and CHPPr theoretically

provide insights about cancer pathways, tumor immunity, and progression landscapes of LSCC. We employed the DESeq2 pipeline (17) to perform DEGA and explore the differentially expressed genes in the three panels separately.

For the pathway analysis, we used gene set variation analysis (GSVA) (18) to investigate the enrichment score (ES) of all the pathways included in The Molecular Signatures Database (MSigDB) Hallmark Gene Set Collection (19). ES of a pathway indicates its activity within each sample. GSVA is a variant of single-sample gene set enrichment analysis (GSEA) (20). We aimed to focus on (I) different biological processes, including signaling, proliferation, pathway, metabolic, immune, DNA damage, development, cellular components, and others (21) and (II) cell type-specific signals (22), which describe the tumor microenvironment (TME). The pathways of the aforementioned biological processes originate from the Hallmark gene set, while the cell-type specific signals are markers from the previous study, which includes 24 different cell types (22).

### *Validation analyses*

We downloaded GSE74777, GSE37745, GSE162520, and GSE161537 from Gene Expression Omnibus (GEO) database and extracted gene expression and clinical data of LSCC cases (n=107, 66, 45, and 17, respectively) to validate the prognosis and immunogenicity significance of *SLC22A3* on LSCC.

We conducted Kaplan-Meier OS analyses on GSE74777 and GSE37745 separately and on the combined cohort of these datasets, which were generated using the value-binning technique. Value-binning is a commonly used technique in data analysis that discretizes data into a predefined number (B) of bins, thereby facilitating cross-platform data management (23). We applied a simple value-binning method to categorize *SLC22A3* gene expression values into B bins, discretizing expression values from 1 to B. We selected B =107 (corresponding to the sample number of the larger dataset) because each value can be assigned to a gene expression value in both datasets. This process can be deemed non-parametric scaling. Our goal was to remove the “magnitude” effect, which is easily confounded by cross-platform differences, and normalize the expression value, which creates the same range of value in both datasets for further non-parametric analyses. This technique was also performed by another study (24). We used the maximally selected rank statistics (MSRS) technique to determine the

survival cutpoint of the *SLC22A3* expression in validation data, which is also a non-parametric analysis, to find the most significant prognostic cut-off in each dataset. The cut-off bins of GSE37745 and GSE74777 were 40 and 95, respectively. This result indicated the differences in clinicopathological characteristics of the two examined cohorts. Therefore, we used the corresponding cut-off of each dataset to divide the sample into *SLC22A3*-high and *SLC22A3*-low samples.

We validated the immunogenicity impact of *SLC22A3* on LSCC by utilizing the Hot Oral Tumor (HOT) score described below. Because the unit of read count was inconsistent between TCGA and validation data, it is impossible to utilize the cut-off of FPKM (fragments per kilobase of exon per million mapped fragments)  $\geq 5$  to determine high expression in the validation data. Therefore, we used the MSRS technique to determine the survival cutpoint of the *SLC22A3* expression in validation data. Based on the HOT score, samples in the TCGA-LUSC cohort were defined as “hot” or “cold” tumors. *SLC22A3* gene expression was compared between the “hot” and “cold” tumor groups in TCGA-LUSC as well as in validation datasets: GSE162520 and GSE161537 [these two datasets were used in the original study on developing HOT score (25)]. Additionally, we conducted OS Kaplan-Meier analyses of *SLC22A3*-low and *SLC22A3*-high LSCC samples in the GSE162520 dataset. We excluded GSE161537 in this survival analysis since the patients of this cohort were treated with immunotherapy, which may confound the result.

### **HOT score**

The HOT score was calculated by using GSEA of the 27-gene list in the original study (25), including *CCL19*, *CCR2*, *CCR4*, *CCR5*, *CD27*, *CD40LG*, *CD8A*, *CXCL10*, *CXCL11*, *CXCL13*, *CXCL9*, *CXCR3*, *CXCR6*, *FASLG*, *FGL2*, *GZMA*, *GZMH*, *IDO1*, *IFNG*, *IRF8*, *LAG3*, *LYZ*, *MS4A1*, *PDCD1*, *TBX21*, *TLR7*, and *TLR8*. LSCC tumors with  $-1 < ES < 0$  or  $0 < ES < 1$  were classified as “cold” or “hot” tumors, respectively. The calculation procedure was performed as in the previous study (25).

### **Statistical analysis**

FPKM, a type of normalized read count, was used as the gene expression unit in this study. By applying a cut-off of 5 FPKM, we divided the LSCC patients into two subgroups


based on their *SLC22A3* expression levels: individuals with high expression (*SLC22A3*-high) and those with low expression (*SLC22A3*-low). To assess the prognosis effect of *SLC22A3*, we employed both non-parametric and parametric analyses, including univariate and multivariate Cox analyses of OS and the Kaplan-Meier curves of OS and DFS rates. The Kaplan-Meier curves compared the OS and DFS rates among patient subgroups categorized by *SLC22A3* expression, chemotherapy, and radiation therapy. The Bioconductor packages, including DESeq2, GSEA, and ChAMP, were employed for bioinformatic analyses using R software version 4.2.2 (The R Foundation, Vienna, Austria). Hypothesis tests were considered significant when  $P < 0.05$  or adjusted  $P$  (if available)  $< 0.05$ . Samples/patients with related missing values were excluded from the corresponding analysis section.

## **Results**

### ***A total of 17.8% LSCCs possess high expression (FPKM $\geq 5$ ) of the SLC22A3 gene***

We first investigated the distribution of *SLC22A3* read counts in the first non-treated samples of primary LSCC using data retrieved from the TCGA-LUSC project ( $n=501$ ), exclusively consisting of LSCC patients (Figure 2A). The mean, median, and standard deviation of the *SLC22A3* expression were 3.3, 1.4, and 6.2, respectively. Choosing the FPKM cut-off to regard low and high gene expression is controversial, depending on the analysis context. Given the range and variation in *SLC22A3* expression, we arbitrarily set  $FPKM \geq 5$  as a high expression. Using this cut-off, we found 17.8% of *SLC22A3*-high LSCCs. For comparison, the read count distribution of *SLC22A1* and *SLC22A2*, which encode other members of the OCT family (OCT1 and OCT2, respectively) in the first samples of primary LSCC, was also examined (Figure S1). We found almost no expression of *SLC22A1* and *SLC22A2* genes in the entire studied cohort.

We then asked which mechanism was involved in the differential expressions of the *SLC22A3* gene in LSCC. DMP analysis indicated the hypomethylation of the *SLC22A3* gene promoter and hypermethylation of the *SLC22A3* gene body in *SLC22A3*-high tumors (Figure 2B). These results implied that the level of *SLC22A3* gene expression in LSCC tumors was perhaps partially attributable to the DNA methylation mechanism.



**Figure 2** Expression and DNA methylation status of *SLC22A3* in LSCC. (A) Distribution of *SLC22A3* gene read counts in LSCC cohort; (B) methylation status of CpG sites of *SLC22A3*-high LSCC. LSCC, lung squamous cell carcinoma; FPKM, fragments per kilobase of exon per million mapped fragments; LFC, log<sub>2</sub> fold change.

### Clinicopathological analysis showed worse prognoses in *SLC22A3*-high patients of TCGA-LUSC cohort

Table 1 illustrates the difference in clinical characteristics (age, gender, race, stage, treatment) of *SLC22A3*-low and *SLC22A3*-high LSCC. Only two different variables, T stage ( $P=0.004$ ) and chemotherapy ( $P=0.01$ ), were different between *SLC22A3*-low and *SLC22A3*-high LSCC. The *SLC22A3*-high tumor showed a higher distribution of T1 (33.7% vs. 20.4%), T3 (18.0% vs. 13.3%), and T4 (6.7% vs. 4.1%) stages while the T2 stage is more dominant in *SLC22A3*-low compared to *SLC22A3*-high LSCCs (62.1% vs. 41.6%). *SLC22A3*-high patients (15.7%) received chemotherapy less frequently than *SLC22A3*-low patients (31.8%).

In survival analysis, we performed both non-parametric and parametric analyses. In the non-parametric method, the Kaplan-Meier curves compared the OS and DFS patterns (Figure 3) of patients stratified by *SLC22A3* expression, chemotherapy, and radiation therapy. OS curves showed that high expression of *SLC22A3* was associated with worse prognoses regardless of chemotherapy and radiation ( $P<0.05$ ) (Figure 3A-3E). DFS curves also revealed a substantial difference between *SLC22A3*-high and *SLC22A3*-low individuals, particularly in groups treated solely with radiation ( $P<0.001$ ) (Figure 3F-3J). Staging-stratified Kaplan-Meier curves based on the AJCC staging system showed that *SLC22A3*-high was associated with worse outcomes in stage II and IV patients (Figure 3K-3N).

In the parametric method, we performed univariate and multivariate Cox analyses of OS to determine the prognostic effects of *SLC22A3* expression (Table 2).

Univariate Cox analysis suggested that *SLC22A3*-high, T3 and T4 of T stage, distant metastatic status, AJCC stage III and IV, and radiation therapy status all had a detrimental impact on LSCC patients' outcomes ( $P<0.05$ ). Only significant variables in univariate analysis were included in the subsequent multivariate section. Overall, *SLC22A3* expression was a prognostic factor in both univariate [hazard ratio (HR) = 1.82; 95% confidence interval (95% CI): 1.32–2.52;  $P<0.001$ ] and multivariate (HR = 2.47; 95% CI: 1.65–3.71;  $P<0.001$ ) evaluations. Additionally, the 5-year OS rates of patients with *SLC22A3*-low and *SLC22A3*-high LSCC were 51.5% (95% CI: 45.4–58.4%) and 22.9% (95% CI: 13.0–40.6%), respectively. The 5-year DFS rates of *SLC22A3*-low and *SLC22A3*-high LSCC were 52.6% (95% CI: 45.3–61.0%) and 35.2% (95% CI: 18.4–67.2%). These results demonstrated that *SLC22A3*-high LSCC had poor prognoses compared to *SLC22A3*-low LSCC.

### Dimension reduction analyses showed *SLC22A3* expression patterns were associated with tumor pathway, immune, and progression landscapes

We performed t-distributed stochastic neighbor embedding (t-SNE) dimension reduction on CHPP, CHIP, and CHPPr gene matrices to explore the distribution of *SLC22A3* expression as both continuous (FPKM) and binary (low/high) variables. In the CHPP panel, we found that *SLC22A3*-high LSCC tended to locate in a locus belonging to the lower left quarter of the graph rather than being evenly distributed (Figure 4A). Our subjective observation was proven by the correlation analysis between

**Table 1** Clinicopathological comparisons of patients with *SLC22A3*-low and *SLC22A3*-high LSCC tumors

Variables	<i>SLC22A3</i> -low (n=412)	<i>SLC22A3</i> -high (n=89)	P value
Age (years), median [range]	69 [39–90]	67 [40–85]	0.459
Gender, n (%)			0.521
Women	104 (25.2)	26 (29.2)	
Men	308 (74.8)	63 (70.9)	
Race, n (%)			0.073
Asian	5 (1.2)	4 (4.5)	
Black	25 (6.1)	5 (5.6)	
White	283 (68.7)	14 (15.7)	
Not reported	99 (24.0)	66 (74.2)	
T stage, n (%)			0.004
T1	84 (20.4)	30 (33.7)	
T2	256 (62.1)	37 (41.6)	
T3	55 (13.3)	16 (18.0)	
T4	17 (4.1)	6 (6.7)	
N stage, n (%)			0.072
N0	257 (62.4)	62 (69.7)	
N1	116 (28.2)	15 (16.9)	
N2	32 (7.8)	8 (9.0)	
N3	4 (1.0)	1 (1.1)	
NX	3 (0.7)	3 (3.4)	
M stage, n (%)			0.668
M0	341 (82.8)	70 (78.7)	
M1	5 (1.2)	2 (2.2)	
MX	63 (15.3)	16 (18.0)	
Not reported	3 (0.7)	1 (1.1)	
AJCC stage, n (%)			0.498
I	197 (47.8)	47 (52.8)	
II	140 (34.0)	22 (24.7)	
III	67 (16.3)	17 (19.1)	
IV	5 (1.2)	2 (2.2)	
Not reported	3 (0.7)	1 (1.1)	
Chemotherapy, n (%)			0.01
No	233 (56.6)	61 (68.5)	
Yes	131 (31.8)	14 (15.7)	
Not reported	48 (11.7)	14 (15.7)	

**Table 1** (continued)

**Table 1** (continued)

Variables	<i>SLC22A3</i> -low (n=412)	<i>SLC22A3</i> -high (n=89)	P value
Radiation therapy, n (%)			0.811
No	303 (73.5)	64 (71.9)	
Yes	59 (14.3)	12 (13.5)	
Not reported	50 (12.1)	13 (14.6)	
Overall survival (years), median [range]	1.9 [0.0–13.1]	1.5 [0.0–14.5]	0.459

LSCC, lung squamous cell carcinoma; AJCC, The American Joint Committee on Cancer.

each t-SNE dimension and *SLC22A3* expression ( $P < 0.001$ , *Figure 4B*, and  $P = 0.003$ , *Figure 4C*). The same logic is applied to interpreting the results in the CHIP (*Figure 4D–4F*) and CHPPr (*Figure 4G–4I*) panels. These results can be interpreted as a possible link between *SLC22A3* expression patterns in LSCC and cancer pathways, cancer-immune interaction, and cancer progression.


#### Pathway analyses showed vastly different oncogenic and TME signals in *SLC22A3*-high LSCCs

We compared the ES between *SLC22A3*-low and *SLC22A3*-high LSCCs in the pathway analysis using Hallmark gene sets (*Figure 5A*) and TME-related analyses (*Figure 5B*). *Figure 5C* shows the skewed distribution of *SLC22A3*-high samples in TME space.

Hallmark gene sets were categorized into eight groups: signaling, proliferation, pathway, metabolic, immune, DNA damage, development, and cellular components, which were used in a previous study (21). *SLC22A3*-high LSCC were characterized by high activity in immune-related pathways such as inflammatory response, IL6-JAK-STAT3, complement, allograft rejection, coagulation, IFN- $\alpha$ , and IFN- $\gamma$  response (adjusted  $P < 0.001$ ). Other pathways also exhibited high activity in *SLC22A3*-high LSCC were KRAS signaling (up), IL2/STAT5, TNF $\alpha$  via NF- $\kappa$ B, EMT, angiogenesis, and TGF- $\beta$  signaling (adjusted  $P < 0.001$ ). On the other hand, the pathways related to proliferation, such as c-MYC targets, G2M checkpoint, and E2F targets, were downregulated in *SLC22A3*-high LSCC (adjusted  $P < 0.001$ ).

In TME-related analyses, *SLC22A3*-high LSCC showed enriched for almost all adaptive immune cells, including B-cells, T-cells, and T-cell subpopulations [T helper 1 (Th1), T gamma delta (Tgd), CD8<sup>+</sup> T, T central memory





**Figure 3** The OS Kaplan-Meier analyses of *SLC22A3*-low and *SLC22A3*-high LSCC samples in the entire cohort (A), chemotherapy and radiation (B), chemotherapy-only (C) radiation-only (D), and neither chemotherapy nor radiation (E) subgroups. The DFS Kaplan-Meier analyses of *SLC22A3*-low and *SLC22A3*-high LSCC samples in the entire cohort (F), chemotherapy and radiation (G), chemotherapy-only (H), radiation-only (I), and neither chemotherapy nor radiation (J) subgroups. Staging-stratified Kaplan-Meier curves of *SLC22A3*-low and *SLC22A3*-high LSCC samples based on AJCC staging system including stage I, II, III, and IV (K, L, M, and N, respectively). OS, overall survival; LSCC, lung squamous cell carcinoma; DFS, disease-free survival; AJCC, American Joint Committee on Cancer.

(Tcm), T effector memory (Tem), and T follicular helper (Tfh), regulatory T (Treg) cells], except T helper 2 (Th2) cells. Innate immune cells such as C56-dim natural killer (NK), dendritic cells (DC), macrophages, mast cells, eosinophils, and neutrophils were abundant in *SLC22A3*-high LSCC. These findings indicated that *SLC22A3*-high LSCC is associated with high activity of immune-related pathways and an intense inflammatory microenvironment compared to *SLC22A3*-low LSCC.


**DEAs illustrated many significant DEGs between *SLC22A3*-low and *SLC22A3*-high tumors**

In CHPP, CHIP, and CHPPr, there were numerous differentially expressed genes between *SLC22A3*-high and *SLC22A3*-low LSCC. Notably, many genes encoding immune checkpoint molecules were upregulated in the *SLC22A3*-high LSCC. In particular, in CHIP, *SLC22A3*-high LSCC expressed higher levels of many immune inhibitory receptors genes, namely: *PDCD1*, *CTLA-4*,

**Table 2** Univariate and multivariate Cox analyses of LSCC patients

Variables	Univariate			Multivariate		
	HR	95% CI	P value	HR	95% CI	P value
<i>SLC22A3</i> expression						
Low	1			1		
High	1.82	1.32–2.52	<0.001	2.47	1.65–3.71	<0.001
Age (years)	1.02	1.00–1.03	0.046	1.03	1.01–1.06	0.003
Gender						
Women	1					
Men	1.2	0.87–1.65	0.264			
Race						
Asian	1					
Black	0.87	0.30–2.59	0.808			
White	0.568	0.21–1.54	0.12			
Not reported	0.44	0.16–1.24	0.266			
T stage						
T1	1			1		
T2	1.24	0.87–1.75	0.232	1.17	0.76–1.79	0.476
T3	1.8	1.15–2.82	0.01	1.32	0.70–2.49	0.389
T4	2.31	1.24–4.31	0.008	1.23	0.47–3.22	0.672
LNM						
No	1					
Yes	1.14	0.86–1.51	0.358			
Distant metastasis						
No	1			1		
Yes	3.07	1.26–7.51	0.014	4.04	1.53–10.70	0.005
AJCC stage						
I	1			1		
II	1.12	0.82–1.55	0.471	1.4	0.94–2.10	0.1
III	1.54	1.08–2.20	0.017	1.11	0.62–1.98	0.737
IV	3.27	1.32–8.06	0.01	N/A	N/A	N/A
Chemotherapy						
No	1					
Yes	0.846	0.61–1.17	0.309			
Radiation therapy						
No	1			1		
Yes	1.5	1.03–2.10	0.032	0.37	0.23–1.65	0.1

LSCC, lung squamous cell carcinoma; HR, hazard ratio; 95% CI, 95% confidence interval; LNM, lymph node metastasis; N/A, not applicable.




**Figure 4** Association between *SLC22A3* expression patterns in LSCC and cancer pathways, cancer-immune interaction, and cancer progression. (A) The t-SNE dimension reduction plot of the PanCancer Pathway panels. Each dot represents an LSCC sample color-coded by *SLC22A3* expression status. The scatter plots (B,C) investigate the linear relationship between each dimension of the t-SNE plot and the continuous normalized read counts of the *SLC22A3* gene. Spearman's correlation analyses were used in these plots. Similar interpretations are used in PanCancer Immune Profile (D-F) and PanCancer Progression (G-I) panels. LSCC, lung squamous cell carcinoma; t-SNE, t-distributed stochastic neighbor embedding.

*TIGIT*, *HAVCR2*, and *BTLA*, which encode programmed cell death protein 1 (PD-1), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), T-cell immunoreceptor with Ig and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3), and B and T lymphocyte attenuator (BTLA), respectively (Table 3). The up-regulation of many genes encoding checkpoint inhibitory molecules in the *SLC22A3*-high LSCC might be

related to the poor prognosis. The full results of DESeq2 analyses are detailed in tables available at <https://cdn.amegroups.com/static/public/tlcr-23-334-1.xlsx>.

#### **Validation on prognostic and immunogenic effects of *SLC22A3* gene expression in LSCC**

When validating the prognostic significance of *SLC22A3* in LSCC patients from GSE37745 and GSE74777



**Figure 5** Pathway analysis of biological processes and cell type-specific signals in *SLC22A3*-low and -high LSCC. (A) The heatmap shows the difference in pathway activity between *SLC22A3*-low and *SLC22A3*-high LSCC samples regarding distinct categories of pathways. These pathways were obtained from the “H” collection in the MSigDB. (B) The heatmap shows the difference in cell type-specific signals between *SLC22A3*-low and *SLC22A3*-high LSCC samples. (C) The t-SNE dimension reduction plot of the TME “space” made of the ES of all the 24-cell type-specific signals shows the different distributions of *SLC22A3*-low and *SLC22A3*-high LSCC samples, indicating there is a relationship between TME and *SLC22A3* expression status. TCGA-LUSC, The Cancer Genome Atlas - Lung Squamous Cell Carcinoma; LSCC, lung squamous cell carcinoma; MSigDB, Molecular Signatures Database; ES, enrichment score; t-SNE, t-distributed stochastic neighbor embedding; TME, tumor microenvironment.


**Table 3** Differentially expressed gene analysis of immune checkpoint molecule genes

Gene name	LFC	Adjusted P value
<i>TNFRSF14</i>	0.505	<0.001
<i>PDCD1</i>	0.751	<0.001
<i>HAVCR2</i>	0.544	<0.001
<i>TIGIT</i>	0.678	<0.001
<i>CD86</i>	0.463	<0.001
<i>CTLA4</i>	0.701	<0.001
<i>CD80</i>	0.665	<0.01
<i>BTLA</i>	0.813	<0.01
<i>CD160</i>	-0.192	>0.05
<i>LAG3</i>	0.271	>0.05
<i>CD274</i>	0.068	>0.05

LFC, log<sub>2</sub> fold change.

cohorts separately, we observed a tendency towards poorer prognoses in *SLC22A3*-high patients compared to *SLC22A3*-low patients, albeit without statistical significance (P=0.078 and 0.07, respectively) (Figure S2A,S2B). These results may be influenced by the relatively limited sample sizes within these cohorts. Therefore, we employed the value-binning technique to merge these two datasets (please refer to the Methods for more details). The combined cohort’s Kaplan-Meier OS curves showed that *SLC22A3*-high expression was linked to poorer prognoses (P<0.001) (Figure 6A).

Our study also found that *SLC22A3*-high tumors were positively correlated with immune-related pathways and an abundance of infiltrating immune cells in the TME. To validate this finding, we utilized the HOT score (25), an interesting metric developed by Foy *et al.*



**Figure 6** Validating prognostic and immunogenic significance of *SLC22A3* gene expression in LSCC (A). The OS Kaplan-Meier analyses of *SLC22A3*-high and *SLC22A3*-low LSCC samples in the GSE37745 and GSE74777 combined cohort. (B) *SLC22A3* expression in “cold” and “hot” tumors of TCGA-LUSC cohort. (C) *SLC22A3* expression in “cold” and “hot” tumors of GSE162520 and GSE161537 combined dataset. TCGA-LUSC, The Cancer Genome Atlas - Lung Squamous Cell Carcinoma; LSCC, lung squamous cell carcinoma; OS, overall survival.

specifically designed to identify tumors with high immunological activity, suggesting potential benefits from immunotherapies. We found that *SLC22A3* expression was consistently higher in “hot” tumors compared to “cold” tumors in both TCGA and validation datasets (Figure 6B,6C). Despite not being statistically significant ( $P=0.22$ ), the results of OS Kaplan-Meier analyses indicated a trend towards poorer prognosis in *SLC22A3*-high patients compared to *SLC22A3*-low patients in GSE162520 dataset (Figure S2C).

## Discussion

Our present study found that *SLC22A3* expression negatively correlated with OS and DFS rates in LSCC patients. Dimension reduction analysis revealed the link between *SLC22A3* expression and cancer pathway, immune landscape, and cancer progression. Pathway analysis showed that, compared to *SLC22A3*-low, *SLC22A3*-high LSCC had higher activity in immune-related pathways such as inflammatory response and IL6-JAK-STAT3 and possessed a bustling TME, with numerous innate/adaptive immune cells infiltrating. There were a lot of differentially expressed genes between *SLC22A3*-high and *SLC22A3*-low LSCC. Notably, many genes encoding immune checkpoint inhibitory molecules were upregulated in the *SLC22A3*-high group. Furthermore, the “hot” LSCC tumor phenotype, as classification based on the HOT score, expressed a higher *SLC22A3* level. These findings indicated

that *SLC22A3*-high LSCC is associated with poor prognosis and positively correlated with immune-related pathways such as inflammatory response and abundance of infiltrating immune cells in the TME.

*SLC22A3*-high LSCC was associated with worse outcomes in LSCC patients (Figure 3). This found result is consistent with earlier studies linking *SLC22A3* expression to unfavorable outcomes in cervical and colorectal cancer. Notably, multivariate Cox analysis solidified *SLC22A3*-high as an independent prognostic factor. In addition, DFS curves suggested that *SLC22A3*-high tumors were particularly resistant to radiotherapy ( $P<0.001$ , Figure 3D). Thus, there is a need for more studies to determine the importance of *SLC22A3* in the pathophysiology and treatment responses of LSCC.

Hallmark gene sets (Figure 5A) and TME-related analyses (Figure 5B) showed that, in comparison to *SLC22A3*-low LSCC, *SLC22A3*-high LSCC is associated with increased activity of immune-related pathways, such as inflammatory response and IL6-JAK-STAT3, and infiltration of almost all innate and adaptive immune cells. These findings suggested that *SLC22A3*-high LSCC undergoes inflammatory signals from the microenvironment where numerous immune cells are infiltrated. The link between inflammation and cancer has become widely accepted and identified as one of cancer’s ten hallmarks (26). Chronic inflammation is either the underlying mechanism of carcinogenesis or the consequence of genetic alterations in tumor cells (27). In addition, inflammation and lung

cancer have been reported to be closely related (28). Inflammation promotes tumor initiation and progression by providing an array of growth and survival factors for tumor cells as well as mediators inducing angiogenesis and the EMT process (27). Of note, angiogenesis and EMT-related pathways activity were also upregulated in *SLC22A3*-high LSCC, which may contribute to the aggressive behavior of these tumors. Interestingly, Li *et al.* have demonstrated that knocking down *SLC22A3* suppressed LPS-induced inflammation in THP-1 cells (29). Further research is needed to fully uncover the role of *SLC22A3* in controlling inflammatory responses, particularly in the tumor context.

On the other hand, the TME-related analyses (Figure 5B) suggested that *SLC22A3*-high LSCC is likely “hotter” (which means tumors with abundant immune cell infiltration) than *SLC22A3*-low LSCC, which was further evaluated using the HOT score—a metric that was specifically designed to identify tumors with high immunological activity. This finding may be a bit surprising since hot tumors are generally assumed to have better outcomes, but our results showed that *SLC22A3*-high LSCC patients had lower OS and DFS rates than *SLC22A3*-low LSCC patients. This contradiction, perhaps, is brought about by the intricate interaction between tumor cells, infiltrating immune cell networks, and soluble components in the TME. T-cell subpopulations, including CD8<sup>+</sup> T-cells, Th1, Tem, Tcm, Tgd, and Tfh, as well as other tumor-infiltrating lymphocytes such as NK cells, B-cells, and DCs, are commonly known to have tumor-protective properties (30-36). However, the presence of these beneficial cells does not guarantee efficient tumor eradication. A broad spectrum of immunosuppressive mechanisms presenting in the TME can impede immune cell function (34,37). These mechanisms, in the context of our study, consist of (I) high expression of multiple immune checkpoint inhibitory molecules; (II) persistence of immunosuppressive cell types such as Tregs; and (III) high activity of the immunosuppressive cytokine TGF- $\beta$  signaling pathway, which possibly confer *SLC22A3*-high tumors with immune evasion ability.

Our study is among the first studies investigating the clinicopathological implications of *SLC22A3* in LSCC. However, there were several limitations. First, our study has not been validated by in-house experiments. Further *in vitro* and *in vivo* studies are needed to examine the causal relationships between biological processes and confirm our observations. Second, the inherent bias of the TCGA database cannot be avoided, including selection bias. For

example, most patients are of Caucasian race. Therefore, it is important to extend the population characteristics to other races. Lastly, our study findings are based on gene expression. It is of value to examine the protein expression of *SLC22A3*. Studies using Western-blot experiments and immunohistochemistry of *SLC22A3* are needed to confirm its value at the protein level and how this protein contributes to the clinical landscape of *SLC22A3*-high LSCC.

## Conclusions

This study found that *SLC22A3*-high LSCC had worse prognoses than *SLC22A3*-low LSCC. Moreover, *SLC22A3*-high LSCC was closely associated with high activity in immune-related pathways and a bustling TME infiltrated by immune cells. These findings suggest that high expression of *SLC22A3* that encodes OCT3 in LSCC is associated with poor prognosis and immunogenicity of the tumor. Understanding the functional implications of *SLC22A3* in LSCC and how it interacts with the immune system may help improve LSCC patient stratification for optimizing immune checkpoint inhibitor therapy treatment, thereby potentially improving outcomes for LSCC patients.

## Acknowledgments

*Funding:* This research was funded by a grant-in-aid for scientific research from the Ministry of Education, Culture, Sports, Science and Technology, Japan (No. 22K19427).

## Footnote

*Reporting Checklist:* The authors have completed the REMARK reporting checklist. Available at <https://tclr.amegroups.com/article/view/10.21037/tclr-23-334/rc>

*Peer Review File:* Available at <https://tclr.amegroups.com/article/view/10.21037/tclr-23-334/prf>

*Conflicts of Interest:* All authors have completed the ICMJE uniform disclosure form (available at <https://tclr.amegroups.com/article/view/10.21037/tclr-23-334/coif>). The authors have no conflicts of interest to declare.

*Ethical Statement:* The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are

appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013).

*Open Access Statement:* This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.


## References

- Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin* 2021;71:209-49.
- Zheng M. Classification and Pathology of Lung Cancer. *Surg Oncol Clin N Am* 2016;25:447-68.
- SEER\*Explorer: An interactive website for SEER cancer statistics [Internet]. Surveillance Research Program, National Cancer Institute; 2023 Apr 19. [updated: 2023 Jun 8; cited 2023 Oct 12]. Available online: <https://seer.cancer.gov/statistics-network/explorer/>. Data source(s): SEER Incidence Data, November 2022 Submission (1975-2020), SEER 22 registries.
- Niu Z, Jin R, Zhang Y, et al. Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials. *Signal Transduct Target Ther* 2022;7:353.
- Reck M, Rodríguez-Abreu D, Robinson AG, et al. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. *J Clin Oncol* 2019;37:537-46.
- Sezer A, Kilickap S, Gümüş M, et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. *Lancet* 2021;397:592-604.
- Ingoglia F, Visigalli R, Rotoli BM, et al. Functional characterization of the organic cation transporters (OCTs) in human airway pulmonary epithelial cells. *Biochim Biophys Acta* 2015;1848:1563-72.
- Nishimura M, Naito S. Tissue-specific mRNA expression profiles of human ATP-binding cassette and solute carrier transporter superfamilies. *Drug Metab Pharmacokinet* 2005;20:452-77.
- Mohelnikova-Duchonova B, Brynychova V, Hlavac V, et al. The association between the expression of solute carrier transporters and the prognosis of pancreatic cancer. *Cancer Chemother Pharmacol* 2013;72:669-82.
- Lian Q, Xiao S, Wang Y, et al. Expression and clinical significance of organic cation transporter family in glioblastoma multiforme. *Ir J Med Sci* 2022;191:1115-21.
- Huo X, Zhou X, Peng P, et al. Identification of a Six-Gene Signature for Predicting the Overall Survival of Cervical Cancer Patients. *Onco Targets Ther* 2021;14:809-22.
- Ren A, Sun S, Li S, et al. Genetic variants in SLC22A3 contribute to the susceptibility to colorectal cancer. *Int J Cancer* 2019;145:154-63.
- Hsu CM, Lin PM, Chang JG, et al. Upregulated SLC22A3 has a potential for improving survival of patients with head and neck squamous cell carcinoma receiving cisplatin treatment. *Oncotarget* 2017;8:74348-58.
- Gu J, Dong D, Long E, et al. Upregulated OCT3 has the potential to improve the survival of colorectal cancer patients treated with (m)FOLFOX6 adjuvant chemotherapy. *Int J Colorectal Dis* 2019;34:2151-9.
- Shnitsar V, Eckardt R, Gupta S, et al. Expression of human organic cation transporter 3 in kidney carcinoma cell lines increases chemosensitivity to melphalan, irinotecan, and vincristine. *Cancer Res* 2009;69:1494-501.
- Morris TJ, Butcher LM, Feber A, et al. ChAMP: 450k Chip Analysis Methylation Pipeline. *Bioinformatics* 2014;30:428-30.
- Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol* 2014;15:550.
- Hänzelmann S, Castelo R, Guinney J. GSEA: gene set variation analysis for microarray and RNA-seq data. *BMC Bioinformatics* 2013;14:7.
- Liberzon A, Birger C, Thorvaldsdóttir H, et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. *Cell Syst* 2015;1:417-25.
- Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci U S A* 2005;102:15545-50.
- Satpathy S, Krug K, Jean Beltran PM, et al. A proteogenomic portrait of lung squamous cell carcinoma. *Cell* 2021;184:4348-4371.e40.
- Bindea G, Mlecnik B, Tosolini M, et al. Spatiotemporal


- dynamics of intratumoral immune cells reveal the immune landscape in human cancer. *Immunity* 2013;39:782-95.
23. Jung S, Bi Y, Davuluri RV. Evaluation of data discretization methods to derive platform independent isoform expression signatures for multi-class tumor subtyping. *BMC Genomics* 2015;16 Suppl 11:S3.
  24. Cui H, Wang C, Maan H, et al. scGPT: Towards Building a Foundation Model for Single-Cell Multi-omics Using Generative AI. doi: 10.1101/2023.04.30.538439.
  25. Foy JP, Karabajakian A, Ortiz-Cuaran S, et al. Immunologically active phenotype by gene expression profiling is associated with clinical benefit from PD-1/PD-L1 inhibitors in real-world head and neck and lung cancer patients. *Eur J Cancer* 2022;174:287-98.
  26. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell* 2011;144:646-74.
  27. Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. *Nature* 2008;454:436-44.
  28. Gomes M, Teixeira AL, Coelho A, et al. The role of inflammation in lung cancer. *Adv Exp Med Biol* 2014;816:1-23.
  29. Li L, He M, Zhou L, et al. A solute carrier family 22 member 3 variant rs3088442 G→A associated with coronary heart disease inhibits lipopolysaccharide-induced inflammatory response. *J Biol Chem* 2015;290:5328-40.
  30. Wang SS, Liu W, Ly D, et al. Tumor-infiltrating B cells: their role and application in anti-tumor immunity in lung cancer. *Cell Mol Immunol* 2019;16:6-18.
  31. Villegas FR, Coca S, Villarrubia VG, et al. Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. *Lung Cancer* 2002;35:23-8.
  32. Stevens D, Ingels J, Van Lint S, et al. Dendritic Cell-Based Immunotherapy in Lung Cancer. *Front Immunol* 2020;11:620374.
  33. Basu A, Ramamoorthi G, Albert G, et al. Differentiation and Regulation of T(H) Cells: A Balancing Act for Cancer Immunotherapy. *Front Immunol* 2021;12:669474.
  34. Thommen DS, Schumacher TN. T Cell Dysfunction in Cancer. *Cancer Cell* 2018;33:547-62.
  35. Kennedy R, Celis E. Multiple roles for CD4+ T cells in anti-tumor immune responses. *Immunol Rev* 2008;222:129-44.
  36. Raskov H, Orhan A, Christensen JP, et al. Cytotoxic CD8(+) T cells in cancer and cancer immunotherapy. *Br J Cancer* 2021;124:359-67.
  37. Harlin H, Kuna TV, Peterson AC, et al. Tumor progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascites. *Cancer Immunol Immunother* 2006;55:1185-97.

**Cite this article as:** Nguyen TA, Le MK, Nguyen PT, Tran NQV, Kondo T, Nakao A. *SLC22A3* that encodes organic cation transporter-3 is associated with prognosis and immunogenicity of human lung squamous cell carcinoma. *Transl Lung Cancer Res* 2023;12(10):1972-1986. doi: 10.21037/tlcr-23-334





**Figure S1** Distribution of *SLC22A1* (A) and *SLC22A2* (B) gene read counts in LSCC cohort. LSCC, lung squamous cell carcinoma; FPKM, fragments per kilobase of exon per million mapped fragments.



**Figure S2** The OS Kaplan-Meier analyses of *SLC22A3*-high and *SLC22A3*-low LSCC samples in the GSE37745 (A), GSE74777 (B), and GSE162520 (C) datasets. OS, overall survival; LSCC, lung squamous cell carcinoma.